Aktuelle therapeutische Konzepte bei Osteosarkomen

Osteosarkome sind durch aggressives Wachstum mit Zerstörung des umliegenden Knochens und gegebenenfalls Gelenks gekennzeichnet. Im multimodalen Therapiekonzept kommen die systemische Chemotherapie nach etablierten Studienprotokollen sowie die lokale Resektion zum Einsatz.

• Literatur

• 1 Bielack S, Carrle D, Casali PG. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl. 04) 137-139
• 2 Bruland OS. et al. Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res 2005; 11: 4666-4673
• 3 Marina NM. et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol 2016; 17: 1396-1408
• 4 Bielack SS. et al. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. J Clin Oncol 2015; 33: 2279-2287
• 5 Smeland S. et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer 2019; 109: 36-50
• 6 Ferrari S. et al. EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma. Tumori 2018; 104: 30-36
• 7 Cesari M. et al. Periosteal osteosarcoma: a single-institution experience. Cancer 2011; 117: 1731-1735
• 8 Laitinen M. et al. The prognostic and therapeutic factors which influence the oncological outcome of parosteal osteosarcoma. Bone Joint J 2015; 97-b: 1698-1703
• 9 Durr HR. et al. Resection margins in bone tumors: what is adequate?. Unfallchirurg 2014; 117: 593-599
• 10 He F. et al. Effects of resection margins on local recurrence of osteosarcoma in extremity and pelvis: Systematic review and meta-analysis. Int J Surg 2016; 36-a: 283-292
• 11 Aponte-Tinao LA. et al. What Are the Risk Factors and Management Options for Infection After Reconstruction With Massive Bone Allografts?. Clin Orthop Relat Res 2016; 474: 669-673
• 12 Grimer RJ. et al. Very long-term outcomes after endoprosthetic replacement for malignant tumours of bone. Bone Joint J 2016; 98-b: 857-864
• 13 Schwarz R. et al. The role of radiotherapy in oseosarcoma. Cancer Treat Res 2009; 152: 147-164
• 14 Longhi A. et al. Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients. Eur J Cancer 2017; 74: 9-16
• 15 Xu J, Guo W, Xie L. Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?. BMC Cancer 2018; 18: 987
• 16 Xiao X, Wang W, Wang Z. The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma. Paediatr Drugs 2014; 16: 503-512
• 17 Harting MT. et al. Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J Pediatr Surg 2006; 41: 194-199
• 18 Ohba T. et al. Pleiotropic effects of bisphosphonates on osteosarcoma. Bone 2014; 63: 110-120
• 19 Chou AL. et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer 2009; 115: 5339-5348
• 20 Picci M. et al. Atlas of musculoskeletal tumors and tumorlikes lesions. 2014